

Protalix BioTherapeutics, Inc.  
Form 8-K  
January 03, 2017

---

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): January 3, 2017**

---

**Protalix BioTherapeutics, Inc.**

**(Exact name of registrant as specified in its charter)**

---

**Delaware  
(State or other jurisdiction  
of incorporation)**

**001-33357**

**(Commission File Number)**

**65-0643773  
(IRS Employer**

**Identification No.)**



**Item 8.01. Other Events**

On January 3, 2017, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing positive interim results from the Company’s phase II clinical trial of alidornase alfa for the treatment of Cystic Fibrosis for the first 13 CF patients enrolled in the study. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

**Item 9.01. Financial Statements and Exhibits**

**(d) Exhibits**

99.1 Press release dated January 3, 2017.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PROTALIX  
BIOTHERAPEUTICS, INC.**

Date: January 3, 2017 By: /s/ Moshe Manor  
Name: Moshe Manor  
Title: Chief Executive Officer